1 – 22 of 22
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
2024) In Annals of Neurology(
- Contribution to journal › Article
-
Mark
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : An observational cohort study
(
- Contribution to journal › Article
- 2023
-
Mark
Cerebrospinal fluid levels of neuroinflammatory biomarkers are increased in athletes with persistent post-concussive symptoms following sports-related concussion
(
- Contribution to journal › Article
-
Mark
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
2023) In Journal of Neurology, Neurosurgery and Psychiatry(
- Contribution to journal › Article
-
Mark
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
(
- Contribution to journal › Article
- 2022
-
Mark
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
(
- Contribution to journal › Article
-
Mark
Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia
(
- Contribution to journal › Article
- 2020
-
Mark
A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
(
- Contribution to journal › Article
-
Mark
Quantification of Plasma Kynurenine Metabolites Following One Bout of Sprint Interval Exercise
(
- Contribution to journal › Article
-
Mark
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
(
- Contribution to journal › Article
-
Mark
Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
(
- Contribution to journal › Article
- 2013
-
Mark
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
(
- Contribution to journal › Article
- 2011
-
Mark
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
(
- Contribution to journal › Article
- 2009
-
Mark
Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta
(
- Contribution to journal › Article
-
Mark
Identification of gene regions regulating inflammatory microglial response in the rat CNS after nerve injury
(
- Contribution to journal › Article
- 2008
-
Mark
Vra4 congenic rats with allelic differences in the class II transactivator gene display altered susceptibility to experimental autoimmune encephalomyelitis
(
- Contribution to journal › Article
-
Mark
Genetic analysis of neuropathic pain-like behavior following peripheral nerve injury suggests a role of the major histocompatibility complex in development of allodynia
(
- Contribution to journal › Article
- 2007
-
Mark
The axon reaction : identifying the genes that make a difference
(
- Contribution to journal › Article
- 2006
-
Mark
Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes
(
- Contribution to journal › Article
- 2005
-
Mark
Genetic dissection of neurodegeneration and CNS inflammation
(
- Contribution to journal › Article
- 2003
-
Mark
Discrete gene loci regulate neurodegeneration, lymphocyte infiltration, and major histocompatibility complex class II expression in the CNS
2003) In The Journal of Neuroscience : the official journal of the Society for Neuroscience 23(30). p.23-9817(
- Contribution to journal › Article